See more : MARX Biotech Co., Ltd. (7731.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Perseus Proteomics Inc. (4882.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Perseus Proteomics Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Creotech Instruments S.A. (CRI.WA) Income Statement Analysis – Financial Results
- Jiangsu Huahong Technology Co., Ltd. (002645.SZ) Income Statement Analysis – Financial Results
- Salesforce, Inc. (CRM.NE) Income Statement Analysis – Financial Results
- Nucleus Financial Group plc (NUC.L) Income Statement Analysis – Financial Results
- BioPharma Credit PLC (BPCP.L) Income Statement Analysis – Financial Results
Perseus Proteomics Inc. (4882.T)
About Perseus Proteomics Inc.
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 100.40M | 94.20M | 71.93M | 67.95M | 85.00M |
| Cost of Revenue | 12.72M | 7.67M | 4.18M | 3.85M | 6.00M |
| Gross Profit | 87.69M | 86.53M | 67.75M | 64.10M | 79.00M |
| Gross Profit Ratio | 87.33% | 91.86% | 94.18% | 94.34% | 92.94% |
| Research & Development | 616.00M | 494.00M | 308.00M | 313.00M | 713.00M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 366.00M | 290.00M | 231.00M | 162.00M | 891.00M |
| Other Expenses | 414.00K | 300.00K | -18.62M | -169.00K | 0.00 |
| Operating Expenses | 982.41M | 784.30M | 539.94M | 475.85M | 919.00M |
| Cost & Expenses | 995.13M | 791.97M | 544.13M | 479.70M | 925.00M |
| Interest Income | 46.00K | 55.00K | 49.00K | 24.00K | 315.00K |
| Interest Expense | 5.53M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.50M | 5.71M | 2.96M | 55.00K | 812.00M |
| EBITDA | -892.00M | -692.00M | -471.00M | -411.23M | -839.64M |
| EBITDA Ratio | -888.43% | -633.32% | -491.89% | -604.17% | -32.94% |
| Operating Income | -894.73M | -697.77M | -472.20M | -411.75M | -812.00M |
| Operating Income Ratio | -891.15% | -740.72% | -656.45% | -605.99% | -955.29% |
| Total Other Income/Expenses | -207.80M | -87.30M | -125.10M | -289.00K | -27.41M |
| Income Before Tax | -1.10B | -785.07M | -597.10M | -411.29M | -840.00M |
| Income Before Tax Ratio | -1,098.12% | -833.40% | -830.08% | -605.31% | -988.24% |
| Income Tax Expense | 1.93M | 1.93M | 1.93M | 1.93M | 1.00M |
| Net Income | -1.10B | -787.00M | -599.02M | -413.22M | -841.00M |
| Net Income Ratio | -1,100.04% | -835.45% | -832.76% | -608.14% | -989.41% |
| EPS | -93.69 | -66.93 | -54.47 | -59.03 | -120.15 |
| EPS Diluted | -93.69 | -66.93 | -54.47 | -59.03 | -92.25 |
| Weighted Avg Shares Out | 11.79M | 11.76M | 11.00M | 7.00M | 7.00M |
| Weighted Avg Shares Out (Dil) | 11.79M | 11.76M | 11.00M | 7.00M | 9.12M |
Source: https://incomestatements.info
Category: Stock Reports